Regular Article
Retention in the Endoplasmic Reticulum as a Mechanism of Dominant-negative Current Suppression in Human Long QT Syndrome

https://doi.org/10.1006/jmcc.2000.1263Get rights and content

Abstract

Mutations in the cardiac potassium channel HERG (KCNH2) cause chromosome 7-linked long QT syndrome (LQT2) characterized by a prolonged QT interval, recurrent syncope and sudden cardiac death. Most mutations in HERG exhibit ««loss of function»» phenotypes with defective channels either inserted into the plasma membrane or retained in the endoplasmic reticulum. ««Loss of function»» mutations reduce IKr, the cardiac delayed rectifier current encoded by HERG, due to haploinsufficiency or suppression of wild-type function by a dominant-negative mechanism. One explanation for dominant-negative current suppression is that mutant subunits render tetrameric channel complexes non-conducting on co-assembly. In the present paper we describe an alternative mechanism for this phenomenon. We show (1) that the dominant-negative HERG mutation A561V is retained in the endoplasmic reticulum and (2) that wild-type channels are tagged for retention in the ER by co-assembly with trafficking deficient A561V subunits. Thus, in HERG A561V dominant-negative suppression of wild-type function is the result of an acquired trafficking defect.

References (30)

  • SG Priori et al.

    Genetic and molecular basis of cardiac arrhythmias: impact on clinical management

    Eur Heart J

    (1999)
  • PJ Schwartz et al.

    Long QT syndrome

    In Zipes DP, Jalife J (ed), Cardiac electroÍphysiology: from cell to bedside. Philadelphia, PA: Saunders

    (2000)
  • MC Sanguinetti et al.

    Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia

    Proc Natl Acad Sci USA

    (1996)
  • M Furutani et al.

    Novel mechanism associated with an inherited cardiac arrhythmia

    Circulation

    (1999)
  • Z Zhou et al.

    Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome

    J Biol Chem

    (1999)
  • Cited by (93)

    • Molecular pathogenesis of long QT syndrome type 2

      2016, Journal of Arrhythmia
      Citation Excerpt :

      He was the first to describe subclasses of class 2 LQT2 mutations [71], the role of Kv11.1a binding domain for pharmacological correction [67], and the regulation of Kv11.1a trafficking by Hsp90/Hsp70 [44]. He made several other seminal discoveries related to Kv11.1a channels [81–88]. Eckhard׳s work was always innovative and he was very helpful to many investigators.

    • Inhibitors of hERG channel trafficking: A cryptic mechanism for QT prolongation

      2013, Annual Reports in Medicinal Chemistry
      Citation Excerpt :

      Because of the tetrameric nature of the hERG channel, a dominant-negative phenotype can also be operative in the channel complex of heterozygotes that can lead to the targeting of the wild-type channels for degradation by the mutant protein or produce a dysfunctional channel.32–35 The A561V mutant provides an illustrative example of this phenomenon.32 The hERG channel is also subject to posttranslational modifications that can modulate both function and cell surface expression, the latter via effects on channel synthesis and trafficking or endocytosis.2

    • RNA interference targeting E637K mutation rescues hERG channel currents and restores its kinetic properties

      2013, Heart Rhythm
      Citation Excerpt :

      Defective trafficking had been previously implicated in hERG channel dysfunction.34 Several mutations, such as G572R and A561V, had been shown to cause trafficking defects, resulting in large reductions in current and a marked decrease in cell surface expression of hERG channels.20,35 In our study, we showed that siRNA treatment led to a significant decrease in the level of E637K-hERG protein but did not affect the level of WT-hERG.

    View all citing articles on Scopus

    Please address all correspondence to: Dr E. Ficker or Dr A. M. Brown, Rammelkamp Center, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109. Fax: 216 749 3889. E-mail: [email protected]

    View full text